BiotechTube

CUDC-907

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Conditions

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Trial Timeline

Jul 1, 2016 → May 28, 2019

NCT ID
NCT02674750

About CUDC-907

CUDC-907 is a phase 2 stage product being developed by Curis for Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations. The current trial status is completed. This product is registered under clinical trial identifier NCT02674750. Target conditions include Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02909777Phase 1Completed
NCT02674750Phase 2Completed
NCT02307240Phase 1Completed

Competing Products

20 competing products in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from Curis

chondrocyte-alginate gel suspensionPhase 3
69
Emavusertib + ZanubrutinibPhase 2
44
CA-4948Phase 2
44
Emavusertib + IbrutinibPhase 1/2
33
Emavusertib + Venetoclax + EmavusertibPhase 1/2
33